Sonoma Pharmaceuticals, a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, has received three new regulatory approvals from the United Arab Emirates Ministry of Health & Prevention.
The first approval is for Acuicyn eyelid and eyelash hygiene, an antimicrobial solution (hypochlorous acid) indicated to treat symptoms and causes of blepharitis on the eyelid and eyelash. Acuicyn kills microorganisms which can cause irritation, infection and ocular surface disease.
The second approval is for Microsafe Oral Care, an antiseptic mouth and throat rinse (hypochlorous acid) that eliminates harmful bacteria, viruses and fungi. It relieves symptoms of pain and inflammation caused by mucositis while accelerating the healing process of wounds and ulcerations in the oral cavity and throat.
The final approval is for Sinudox Nasal Cleansing Spray, an antimicrobial solution (hypochlorous acid) intended for nasal irrigation to penetrate, clear and clean the nasal passages and sinus cavity in post-operative, preventative and symptomatic nasal care.
"The regulatory process in the United Arab Emirates is extremely rigorous and considered the gold standard for Southwest Asian nations. Therefore, securing these three UAE approvals will certainly open the path to growth and help expedite regulatory approvals from many other countries in the region," said Safwan Abdallah, MicroSafe Group's director of operations. "We anticipate launching all three products across the United Arab Emirates in February 2018."
"The MicroSafe group continues to build with our proprietary hypochlorous acid platform throughout the Middle East with approvals and products across dermatology, wound care, disinfectants and now personal care. We are very excited for the MicroSafe Group and honoured to be partnered with them," said Bruce Thornton, VP of international operations for Sonoma Pharmaceuticals.